INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH

# LIPID BASED NANOPARTICLES IN CANCER THERAPY

**Prashant Purohit*, Himisha Gaur**

*Department of Pharmaceutics, Swami Keshvanand Institute of Pharmacy, Bikaner (Raj)-334001, India.*

**ARTICLE INFO**

**Article history**
Received 17/07/2023
Available online
31/07/2023

**Keywords**
Lipid Based Nanoparticles,
Liposome,
Solid Liquid Nanoparticles,
Tumour.

**ABSTRACT**

Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs (Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy has transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.

***Corresponding author***
**Prashant Purohit**
Department of Pharmaceutics,
Swami Keshvanand Institute of Pharmacy, Bikaner (Raj)-334001, India.
prashantskip@gmail.com

*Please cite this article in press as **Prashant Purohit** et al. Lipid Based Nanoparticles in Cancer Therapy. Indo American Journal of Pharmaceutical Research.2023:13(07).*

## INTRODUCTION

Tumour is a category of illness that is explained as irregular cell development with ability to spread toward other cells or areas of the body. It is among the biggest killers, of over 100 distinct forms of cancer. Inside the undeveloped nation, diseases like H. pylori, hbv, hep C, hpv infection, Epstein–Barr viruses, and HIV cause 15% of malignancies. Those variables function, at least in part, through altering a cell's genes. Many genetic alterations are often necessary before cancer starts. Cancers are caused by inherited genetic abnormalities in 5–10% of cases. Various indications & indicators, as well as medical tests, can help identify malignancy. It would then be generally explored forward with diagnostic imaging & verified with a biopsy. During 2015, around 90.5 million individuals were diagnosed with cancer [1]. Annually, nearly 18 million new cases are recorded in 2019. It was blamed for almost 8.8 million deaths each and every year. Lung cancer, prostate cancer, colorectal cancer, and stomach cancer are the most prevalent kinds of cancer in men. Breast cancer, colorectal cancer, lung cancer, and cervical cancer are the most prevalent kinds of cancer in women. Skin cancers other than melanoma would account for around 40percent of new cases of cancer per year if total new cancer cases had been included. Acute lymphoblastic & brain cancer seem to be the most frequent in youngsters, other than in African, wherein non-Hodgkin cancer is more frequent [2-3].

Tumor nanotechnology has now been created as a potential cancer therapeutic method for antitumor drug deliver. Nanoparticles have diameters ranging from 1 to 1000 nm and boost therapeutic bioavailability as well as anticancer drug specificity. Because of their distinctive optical characteristics, broad excitation spectrum, and overly limited symmetric intensity distribution, semiconductor quantum dots (QDs) may now be used as a flexible material system with tremendous promise for biological applications. Semiconductor QDs are an exciting new class of fluorescence components. They are employed in bioimaging, biolabeling, and biosensing applications. QDs have a greater impact than ordinary fluorophores [4-5]. They are brighter, have more fluorescence intensity controllability, and are less photobleached. Different colored QDs may be excited by a single source of light and have broad absorption and narrow emission spectra. The aforementioned QDs appear to be the best alternative for screening cell receptors. To generate effective fluorescence probes, the surface of QDs must be changed utilising various biological substances [6].




**Figure 1. The overall arrangement of solid lipid nanoparticles, which have benefits over liposomes and lipid emulsions, is represented schematically.**

## SOLID LIPID NANOPARTICLES (SLN)

These are hard sized ranged between 1-1000nanometer. The size of particles mostly between 150-300nanometer. SLNs are solid, submicronic colloidal nanocarriers with a size range of 1e1000 nm. The particle size is mainly between 150 and 300 nm. Such delivery of drugs methods, like polymeric nanoparticles, provide a framework for regulated releases. Their solid matrix of SLNs allows them to restrict medication motility & offer better stabilization, allowing them to combine the benefits of polymeric nanoparticles, liposomes, and micronized emulsifiers. Moreover, tests show that SLNs were highly advantageous in a variety of aspects, such as the prevention of utilising organic solvent while manufacturing, possible scaling, as well as the inclusion both of lipophilic and hydrophilic medicines in significant quantities. SLNs are created by replacing a solid lipid or even a combination of solid lipids for the liquid lipid (oil) in the structure of oil in water emulsion. One important feature of SLNs is that they have been solid at both room as well as temperature of body. Such drug transport systems are composed of 0.1–30% (w/w) solid lipid dispersed in an aqueous medium. SLNs are typically composed of solid form lipid such as higher purity of triglycerides, free fatty acids, free fatty alcohols, complex glyceride blends, and even wax (typically well-known physiologic lipids). It is also feasible to use more complicated structures [7-8].

**Limitations of SLN and way to overcome**

Although SLNs are most often made up of solid lipid, degradation and instability may become a concern. Factors that must be considered are including high pressure–induced drug degradation, the coexistence of different lipid modifications and colloidal species, the minimal drugloading potential, and the kinetics of delivery process [9].

**High pressure–induced drug degradation**

Molecular size & structure are the primary causes of drug degradation, and high pressure homogeneity has also been shown to reduce polymeric molecular weight. High molecular weight composites or chain length elements are much more vulnerable than low molecular compounds with a spherical form, despite the fact that several studies show that high-pressure homogenization–induced drug degradation is not a concern for the overwhelming bulk of bioactive metabolites. Nevertheless, large molecular weight chemicals such as DNA, albumin, and dextrose are particularly vulnerable to breakage; hence, a separate approach must be used to integrate these elements into SLNs [10].

**Lipid crystallization and drug incorporation**

A further critical factor to take into account is lipid crystallisation. For past decade, researchers have been studying the relationship among lipid alteration and medication administration. The study of lipid changes is well known. The majority of the methods rely on X-ray and differential scanning calorimetric measurements. Nevertheless, the majority of the information has come from studies on huge quantities lipids. Due to the obvious nanosize of the carrier and the huge number of interface active participants needed to maintain the colloidal lipid dispersal, the effectiveness of SLNs may vary significantly. As a result, lipid crystallisation and drug inclusion have an impact on lipid particle properties. The following important considerations must be taken into consideration while discussing drugs capture within SLNs: (1) the occurrence of supercooled melts; (2) the occurrence of multiple lipid alterations; (3) the morphology of lipid nanodispersions; and (4) gelation processes [11-12].

**Several colloidal species coexist**

The cohabitation of numerous nanoparticles within SLNs has received little attention from researchers, despite the fact that it is a crucial aspect to address. Surfactants are incorporated on both the lipid surface and the interior. In glycocholate/lecithin stabilised and related systems, heterogeneous micelles must be acknowledged. Because micelles, combined micelles, and liposomes are known to dissolve pharmaceuticals, they can be used as alternative therapeutic inclusion targets. The presence of various heterogeneous entities alone is insufficient to characterize the structure of colloidal lipid phase separation, because dynamic processes are critical for drug stabilization and releasing. As a result, the kinetics of distribution processes must be taken into account. For illustrate, hydrolytic medications will degrade quicker in water dissolved & interface localised compounds than in lipid compounds [13].

The rates of breakdown will be regulated by: (1) the medication's chemical nature, and (2) the drug concentration in the aqueous phase or at the lipid/water boundary. Volatile medications will undergo hydrolysis quickly when they come into touch with liquid, causing the drug's dispersion balance between various habitats to be disrupted. Carriers are only beneficial if they prohibit the medication from being redistributed. Naturally, enhancing the matrix thickness reduces the diffusion coefficient of the medication inside the transporter, hence SLNs are projected to outperform lipid nanoemulsions. To create an effective delivery mechanism, comprehensive transparency about bits' in vitro and in vivo destiny must be provided [14-15].

## MEDICAL APPLICATIONS OF SLN

**Cancer chemoimmunotherapy**

Tumour chemoimmunotherapy would be a medication which combines all beneficial effects of chemotherapeutic with immunotherapeutic. Chemo usually entails use of such traditional cytotoxic medicines as well as new molecularly targeted treatments. Immunotherapy, on the other hand, is a relatively new kind of cancer treatment which employs the sufferer's native immune system to fight cancer cells. It includes the Immune checkpoint inhibitors, adoptive cell therapy, cancer vaccinations, & cytokine therapies are all being used [16].

**Nanoparticles based on lipids in cancer immunotherapy**

Due to specific benefits, nanotech has received a lot of interest in cancer therapy. Nanoparticle, in illustration, such as Polymeric micelles, lipid-based nanoparticles, gold nanoparticles, and inorganic nanoparticles are all examples of nanoparticles, are frequently employed to transport therapeutics including small molecules (either hydrophilic or hydrophobic), protein, & heredity materials for chemotherapeutic agents. Those nanomaterials can transport therapeutic drugs to certain cells via passively focusing techniques like the EPR impact or active targeting techniques like specific ligand. Lipid-based nanoparticles, in particular, have appealing pharmacological & multifunctional properties, such as bio-compatibility, bio-degradability, as well as the potential to intimidate both aquaphilic and aquaphobic therapies. Furthermore, the surface characteristics of lipid-based nanoparticles may be readily changed by changing the lipid components or altering the surface. Presently some of that are under preclinical trails such as hybrid lipid-based nanoparticles, nano discs, & liposomes [17].

**Liposomes**

Liposomes are nanosized particles composed largely of cholesterol and phospholipids that have proven improvements in bio-compatibility and increased directed payloads distribution with little harm. With its lipid soluble ends, amphiphilic phospholipids self-assemble it into circular lipid bilayer form, allowing water insoluble medicines to be enclosed. Water - soluble head of phospholipids, but at the other hand, form an external surface as well as a watery centre which can contain aquaphilic substances. Numerous s medicinal compounds can be encapsulated into liposomes via charge–charge interactions or interactions with chemical linkers on the liposomal surface. Liposomes, which allow for the administering drugs including both lipid and water-soluble therapeutic drugs while maintaining effectiveness, are one of the most effective nanotech medications in cancer treatment. Although PEGylated liposomal DOX (Doxil®) has become the first Food and drug administration approved nano-drug in 1995, the FDA has authorised more than six liposomal medicines to be used in cancer treatment. Liposomes were used as among the most appealing targeted delivery in chemoimmunotherapy, building on the success of liposomes in chemo. Liposomes are the first and mostly explored nanocarriers for cancer drug delivery, which have shown great promise in clinical applications, but their limited accumulation and penetration into the tumor interstitial space, significantly reduce the therapeutic efficacy [18].

**Nano disc**

Nano discs are a synthetic model membrane system comprised of a phospholipid bilayer with the hydrophobic edge filtered by two amphipathic proteins are known as membranes scaffolding proteins (MSP). The MSP in certain nano discs is enhanced apolipoprotein A1 (apoA1), which would be the primary component of high-density lipoproteins (HDL). Nano discs have a shape comparable to discoidal HDL, which simulates a more natural environment then liposomes and micelles. In immunotherapy, this biomimicking delivery method appears to be more successful. Schwendeman's group completed extensive research on nano disc-based chemoimmunotherapy. Originally, they created an HDLmimicking nano-disc that was attached to draining lymph nodes with a neoantigen (Ag peptide) and adjuvant (CpG). The nano-disc evoked upwards to 47-fold more neoantigen specific CTLs then solubilized vaccines and 31-fold more than the clinical trial adjunct. Those findings reinforced a novel potent strategy to cancer immunotherapy [19].

**APPLICATIONS IN CANCER THERAPY**

Lipid-Based NPs (LBNPs) are a vast and diversified class of nanoparticles that are especially important in BreC therapy. But besides their diversity, liposomes are widely employed because to their great biocompatibility and ability to encapsulate a wide range of cargos. LBNPs are now being employed in a number of studies, and a few of them (for example, Doxil® or Abraxane®) have previously been licenced for BreC therapy [6, 38]. This part presents the most recent major breakthroughs in the use of LBNPs in the treatment of the most common kinds of cancer [20].

**Bowel cancer**

Bowel cancer is a major health concern because of its high death rate (it is the second leading cause of death) and the recent increase in its incidence. LBNPs provide a possible method for improving existing treatments, particularly in advanced colorectal cancer where chemotherapy (5-FU alone or in combination with other medicines) or monoclonal antibodies (bevacizumab, trastuzumab, cetuximab) are ineffective. In comparison to a 5-FU thermosensitive gel-mediated microemulsion (ME), a thermosensitive gel-mediated 5-FU microemulsion (ME) was able to enhance Caco-2 permeability and cell uptake, as well as its accumulation in rectal tissue in vivo. A sophisticated device based on Pickering emulsions (PE) that consists of a magnetic cellulose nanocrystal loaded with CUR and is capable of regulated drug release when exposed to an external magnetic field. In both monolayer and multicellular spheroids, this approach inhibited the development of HCT116 cells. Activated macrophages in the tumour environment using lipopolysaccharide (LPS) from attenuated Salmonella bacteria coated with DOX-thermosensitive liposomes and high-intensity focused ultrasonic waves. Through changes in membrane fluidity, this approach was able to enhance DOX internalisation and reduce tumour development in vivo. Liposome characterisation is also being utilised to enhance CRC therapy [20].

**Stomach cancer**

It is the globe's 5th another very frequent malignancy as well as the major cause of malignancy mortality. Only stomach malignancy that has not spread to the lymph nodes could be managed via surgical removal only. Severe stomach carcinoma, should be managed with combination chemotherapy, which have significant adverse impacts. New treatments relying upon nano formulation are currently being explored to enhance patient responses. Liposomes were broadly applied in GC therapy, either alone or in combination with compounds including the Arg-Gly-Asp peptides, SATB1 siRNA/CD44 antibodies, or in the formation of DNA complexes. Their use enhanced drug deposition in cancerous cells of any animals grafted with SGC7901 cells expressing high levels of integrin 51. Liposomes also exhibited increased targeting accuracy and were able to suppress SATB1 gene expression by about 80% in CD44 þ GC starting cells. Furthermore, liposomes recognised peritoneally dispersed GC MKN-45P cells, decreasing their accumulation in the liver. Initial studies using SLNs in GC revealed that etoposide (VP16) had increased action in SGC-7901 cell, increasing inhibition of growth, causing cell arrests in the G2/M stage (17.13 percent), & this method improved the absorption of both anticancer medicines and had a synergistic activity on MGC-803 cells [21].

**Breast tumour**

It is the leading cause of mortality in women and is experiencing significant shifts as a result of the development of NPs, notably in the treatment of metastatic cancer. Throughout the tolerant MCF-7/ADR cancer cell, NEs preloaded with DOX & bromo tetra trandrine (W198, P-glycoprotein (P-gp) inhibitor) have been examined. That increased cellular absorption and deposition of DOX in cancer cells. DOX, on the other hand, reduced stomach & cardiac damage. In contrast, DOX-liposome-based compositions were evaluated in clinical studies. PLD in conjunction to lapatinib have been recently utilised in HER2- positive BreC sufferers (stage Ib) to find the best conjunction including both therapies at the highest acceptable dosage. Furthermore, a phase 3 trials of Myocet in combination with cyclophosphamide (CM) or vinorelbine (MV) in cancer patients BreC has also been established. SLNs are another type of LBNP employed in BreC investigations.

**Glandular carcinoma**

Presently, the primary LBNPs under investigated as potential treatment methods in prostate cancer include NEs, liposomes, and solid-lipid NPs (SLNs) (PrC). An oil-in-water NE containing a toxoid therapeutic agent linked to an omega-3 fatty acid. That NE is effective to lessen the toxoid IC50 of PPT2 cell types 12-fold, enabling for a larger tumour size decrease in tumour-bearing rats than AbraxaneTM. In PC-3 cells, similar antitumor effects were seen when NE was loaded with catechin extract (flavanols having anticancer activities). Regarding liposomes, 22Rv1 PrC cells were treated with PEG-folate-targeted-oleuropein-liposomes [22-23].

## CONCLUSION

Lipid Based Nanoparticles are a varied and comprehensive category of compounds that have been utilised to treat various diseases, most notably malignancy. Liposomes are now the most often utilised Lipid Based Nanoparticles because to its excellent biocompatibility & flexibility; although, SLNs as well as NLCs have lately gained popularity. Nonetheless, studies are just not focused primarily on such Nanoparticles, and there are several papers focusing on novel techniques for utilising Lipid Based Nanoparticles to heal other kinds of cancer. Some of it has already progressed towards the next stage & began new careers in clinical studies. SLNs and nanostructured lipid carriers have received a lot of interest in the recent decade as prospective delivery of drugs (nano) systems. One‘s main benefit may be the utilisation of biomaterial, environmentally safe ingredients and techniques of production (Figure 5). It really should be stressed; however, that prior to mass producible & distribution of these schemes, rigorous clinical and environmental safety analysis must be done. The establishment of standardised processes for assessing possible dangers of nano - materials consumption, as well as the corresponding regulatory environment, is considered necessary. As with other nanosized drug carriers, melanoma therapy is an important research area in which SLNs can be used, which might also represent both large level of funding in the field as well as the appropriateness of nanostructures for such delivering of cytotoxic drugs, owing to the direct and indirect attacking prompted by malignant cellular level. Nonetheless, there are numerous clinical sectors which derive value from using lipid nanoparticles. Regrettably, more research, extra effort & working capital facilities should be provided for SLN/NLC to be shown therapeutically effective in real-world circumstances. For said time being, the rarity of SLNs which have advanced to medical studies suggests that it would be at least a few years before such innovations approach the national or international drug market.

## CONFLICT OF INTEREST

Nil

## ACKNOWLEDGEMENT

The authors are grateful to the authorities of Swami Keshvanand Institute of Pharmacy, Bikaner (Raj) for the facilities

## REFRENCES

1. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet 388 (10053) (8 October 2016) 1545–1602.
2. Marco Sciacovelli, Christina Schmidt, Eamonn R. Maher, Christian Frezza, Metabolic drivers in hereditary cancer syndromes, Annu. Rev. Cell Biol. 4 (2020) 77–97.
3. GBD 2015 Mortality and Causes of Death, Collaborators, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet 388 (10053) (8 October 2016) 1459–1544.
4. Khan, M. Aqil, S.S. Imam, A. Ahad, Y. Sultana, A. Ali, K. Khan, Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: characterization, nasal absorption, histopathology and cell line study, Int. J. Biol. Macromol. 116 (2018) 1260–1267.
5. H. Shmeeda, Y. Amitay, J. Gorin, D. Tzemach, L. Mak, S.T. Stern, Y. Barenholz, A. Gabizon, Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer, J. Drug Target. 24 (2016) 878–889.
6. Prashant Purohit, Sahil., A review on wound healing activity of medicinal plants, IJPDA, 6(2018) 545-547
7. K.C. Mei, Y.P. Liao, J. Jiang, M. Chiang, M. Khazaieli, X. Liu, X. Wang, Q. Liu, C.H. Chang, X. Zhang, et al., Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors, ACS Nano 14 (2020) 13343–13366.

8. T. Lang, Y. Liu, Z. Zheng, W. Ran, Y. Zhai, Q. Yin, P. Zhang, Y. Li, Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer, Adv. Mater. 31 (2019), e1806202.
9. G. Wang, B. Wu, Q. Li, S. Chen, X. Jin, Y. Liu, Z. Zhou, Y. Shen, P. Huang, Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy, Small 16 (2020) 2004172.
10. Q. Lv, L. Cheng, Y. Lu, X. Zhang, Y. Wang, J. Deng, J. Zhou, B. Liu, J. Liu, Thermosensitive exosome-liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer, Adv. Sci. 7 (2020) 2000515.
11. M. Kong, J. Tang, Q. Qiao, T. Wu, Y. Qi, S. Tan, X. Gao, Z. Zhang, Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency, Theranostics 7 (2017) 3276–3292.
12. R. Kuai, W. Yuan, S. Son, J. Nam, Y. Xu, Y. Fan, A. Schwendeman, J.J. Moon, Elimination of established tumors with nanodisc-based combination chemoimmunotherapy, Sci. Adv. 4 (2018), eaao1736.
13. L.M. Scheetz, M. Yu, D. Li, M.G. Castro, J.J. Moon, A. Schwendeman, Synthetic HDL nanoparticles delivering docetaxel and CpG for chemoimmunotherapy of colon adenocarcinoma, Int. J. Mol. Sci. 21 (2020) 1777.
14. R. Kuai, L.J. Ochyl, K.S. Bahjat, A. Schwendeman, J.J. Moon, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat. Mater. 16 (2017) 489–496.
15. M. Kong, J. Tang, Q. Qiao, T. Wu, Y. Qi, S. Tan, X. Gao, Z. Zhang, Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency, Theranostics 7 (2017) 3276–3292.
16. T.Wang, J. Zhang, T. Hou, X. Yin, N. Zhang, Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy, Nanoscale 11 (2019) 13934–13946.
17. García-Pinel, C. Porras-Alcala, A. Ortega-Rodríguez, F. Sarabia, J. Prados, C. Melguizo, J.M. Lopez-Romero, Lipid-based nanoparticles: application and recent advances in cancer treatment, Nanomaterials 9 (4) (2019) 638.
18. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394–424.
19. J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D.M. Parkin, M. Pineros, ~ A. Znaor, F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Cancer 144 (2019) 1941–1953.
20. L.E. Low, L.T.-H. Tan, B.-H. Goh, B.T. Tey, B.H. Ong, S.Y. Tang, Magnetic cellulose nanocrystal stabilized Pickering emulsions for enhanced bioactive release and human colon cancer therapy, Int. J. Biol. Macromol. 127 (2019) 76–84.
21. K. Ektate, M.C. Munteanu, H. Ashar, J. Malayer, A. Ranjan, Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots), Sci. Rep. 8 (2018) 13062.
22. E. Moghimipour, M. Rezaei, Z. Ramezani, M. Kouchak, M. Amini, K.A. Angali, F.A. Dorkoosh, S. Handali, Folic acid-modified liposomal drug delivery strategy
23. Prashant Purohit, Priyanka Mishra, Renu Bhati , Gestational Diabetes Mellitus: An updated Review, RUHS Journal of health sciences. 4(2019) 223-226


54878478451**230707**